Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) EBITDA (2020 - 2025)

Historic EBITDA for Apellis Pharmaceuticals (APLS) over the last 6 years, with Q3 2025 value amounting to $215.9 million.

  • Apellis Pharmaceuticals' EBITDA rose 47726.79% to $215.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.7 million, marking a year-over-year increase of 11813.26%. This contributed to the annual value of -$197.6 million for FY2024, which is 6279.96% up from last year.
  • Apellis Pharmaceuticals' EBITDA amounted to $215.9 million in Q3 2025, which was up 47726.79% from -$41.7 million recorded in Q2 2025.
  • In the past 5 years, Apellis Pharmaceuticals' EBITDA registered a high of $215.9 million during Q3 2025, and its lowest value of -$219.4 million during Q2 2021.
  • Over the past 5 years, Apellis Pharmaceuticals' median EBITDA value was -$138.9 million (recorded in 2022), while the average stood at -$107.7 million.
  • In the last 5 years, Apellis Pharmaceuticals' EBITDA crashed by 28523.16% in 2021 and then skyrocketed by 47726.79% in 2025.
  • Quarter analysis of 5 years shows Apellis Pharmaceuticals' EBITDA stood at -$148.0 million in 2021, then decreased by 10.69% to -$163.8 million in 2022, then soared by 44.43% to -$91.1 million in 2023, then skyrocketed by 59.89% to -$36.5 million in 2024, then surged by 691.12% to $215.9 million in 2025.
  • Its EBITDA stands at $215.9 million for Q3 2025, versus -$41.7 million for Q2 2025 and -$92.0 million for Q1 2025.